{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/gilead-sciences-gild/",
 "dataUrl": "https://clearank.com/stock/gilead-sciences-gild/data.json",
 "title": "Gilead Sciences (GILD) Stock Forecast & Price Target (2026)",
 "description": "Gilead Sciences, Inc. (GILD) stock: Healthcare, Drug Manufacturers - General. $179.6B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Gilead Sciences, Inc. (GILD)",
 "published": "2026-06-17T09:07:47+00:00",
 "modified": "2026-09-11T11:47:26.457+00:00",
 "generated": "2026-09-11T21:15:17.190Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "GILD",
  "name": "Gilead Sciences, Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - General",
  "country": "United States",
  "website": "https://www.gilead.com"
 },
 "quote": {
  "price": 144.81,
  "previousClose": 145.65,
  "change": -0.84,
  "changePercent": -0.58,
  "open": 145.070007,
  "high": 145.91,
  "low": 143.67,
  "volume": 6019300,
  "averageVolume": 5270860,
  "marketCap": 179557905995,
  "fiftyTwoWeekHigh": 157.28999,
  "fiftyTwoWeekLow": 108.46,
  "marketOpen": false,
  "asOf": "2026-09-11T11:47:24.000Z"
 },
 "statistics": {
  "pe": -54.65,
  "eps": -2.65,
  "dividendYield": 0.022651933224252664,
  "beta": 0.35,
  "priceToSales": 5.8954563,
  "priceToBook": 15.191985,
  "revenueTtm": 30456999936,
  "grossMargin": 0.7976419325900295,
  "returnOnEquity": -0.2068
 },
 "technicals": {
  "rsi": 53.04,
  "macd": 3.06,
  "sma50": 137.74,
  "sma200": 134.65,
  "rsiSignal": "Neutral",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Hold",
  "score": 55,
  "consensus": "Hold",
  "fairValue": 144.81,
  "analystTarget": 160,
  "analystCount": 28,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-11T11:47:24.000Z",
  "priceAtAnalysis": 144.81,
  "volatility": {
   "daily": 1.65,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 143.36,
  "aggressiveEntry": 144.81,
  "stopLoss": 139.06,
  "stopLossPercent": 3,
  "targets": [
   147.66,
   150.53,
   154.83
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 111.34,
    "base": 154.52,
    "upside90th": 214.43
   },
   {
    "year": 2028,
    "downside10th": 103.72,
    "base": 164.87,
    "upside90th": 262.07
   },
   {
    "year": 2029,
    "downside10th": 99.72,
    "base": 175.92,
    "upside90th": 310.33
   },
   {
    "year": 2030,
    "downside10th": 97.46,
    "base": 187.71,
    "upside90th": 361.52
   },
   {
    "year": 2031,
    "downside10th": 96.25,
    "base": 200.29,
    "upside90th": 416.78
   },
   {
    "year": 2032,
    "downside10th": 95.77,
    "base": 213.71,
    "upside90th": 476.93
   },
   {
    "year": 2033,
    "downside10th": 95.82,
    "base": 228.04,
    "upside90th": 542.7
   },
   {
    "year": 2034,
    "downside10th": 96.3,
    "base": 243.32,
    "upside90th": 614.79
   },
   {
    "year": 2035,
    "downside10th": 97.14,
    "base": 259.63,
    "upside90th": 693.94
   },
   {
    "year": 2036,
    "downside10th": 98.28,
    "base": 277.03,
    "upside90th": 780.89
   }
  ]
 },
 "faqCount": 8,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "GILD Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$145.07",
    "Day Range": "$143.67 to $145.91",
    "Prev Close": "$145.65",
    "Volume": "6.02M",
    "52-Week Range": "$108.46 to $157.29",
    "Market Cap": "$179.56B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a notable discount to sector peers (-44%), which may indicate undervaluation or specific company headwinds."
   ]
  },
  {
   "id": "financials",
   "title": "GILD Financial Performance",
   "text": [
    "Analysis: In the last 5 quarters, GILD beat estimates 5 times. However, the stock fell 3 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "GILD Analysis",
   "text": [
    "Gilead Sciences (GILD) is trading above its 50-day and 200-day moving averages ($137.74 and $134.65), indicating a generally positive long-term trend, but it is currently below its 20-day EMA, suggesting potential near-term downward pressure. The Relative Strength Index (RSI) is at 53.04, which falls into the neutral momentum category, offering no strong signal of overbought or oversold conditions. Volume has been slightly above average recently, with the latest volume at 6.02 million compared to an average of 5.27 million. Key support levels are around the 50-day SMA of $137.74, while resistance may be encountered near the 20-day EMA of $145.05 and the current price. The MACD indicator is positive at 3.06, suggesting some underlying bullish momentum, but the overall technical picture is mixed due to the price action relative to the shorter-term EMA.",
    "Insiders have sold $99.9 million worth of GILD stock with no reported purchases, indicating a strong bearish sentiment from management and potentially signaling future price weakness.",
    "Gilead Sciences is currently reporting a negative EPS of -$2.65, which raises concerns about the company's profitability and the sustainability of its dividend.",
    "Projected revenue growth for the current quarter is 0.00% year-over-year, indicating a lack of immediate top-line expansion, though modest growth is anticipated in subsequent periods.",
    "The median analyst price target for GILD is $160.00, suggesting a potential 10.5% upside from the current price, supported by a 'Buy' consensus from 28 analysts.",
    "GILD is trading above its 50-day and 200-day moving averages ($137.74 and $134.65), indicating a generally positive long-term trend and potential support levels.",
    "The base case outlook for Gilead Sciences (GILD) over the next 6-12 months suggests a period of consolidation or modest recovery, contingent on improved revenue growth and a potential shift in insider sentiment. While analysts have a median price target of $160.00, implying a 10.5% upside, the current fair value aligns with the stock price, limiting immediate gains. The company's ability to translate its pipeline into consistent revenue growth and profitability will be key to driving the stock higher. Potential catalysts for upside include successful clinical trial results or new drug approvals, which could significantly boost investor confidence and revenue streams. Conversely, continued heavy insider selling, persistent negative EPS, or a failure to accelerate revenue growth could lead to a re-evaluation of the stock's valuation, potentially pushing it towards its lower support levels. The sector's average P/E of 31.9 suggests that if GILD can achieve consistent profitability and growth, there is room for valuation expansion."
   ],
   "lists": {
    "ProTips": [
     "Monitor insider transaction trends closely; the current heavy selling pressure is a significant bearish signal that could precede further price declines.",
     "Given the negative EPS, investors should scrutinize Gilead's cash flow generation and debt levels to assess the sustainability of its dividend and its ability to fund future research and development.",
     "Pay close attention to upcoming earnings reports and forward guidance, as any signs of accelerating revenue growth or improved profitability could serve as a catalyst to reverse the current negative sentiment."
    ]
   },
   "catalysts": [
    {
     "type": "Bearish",
     "title": "Heavy Insider Selling Pressure",
     "text": "Insiders have sold $99.9 million worth of GILD stock with no reported purchases, indicating a strong bearish sentiment from management and potentially signaling future price weakness.",
     "source": "Insider Trading Data"
    },
    {
     "type": "Bearish",
     "title": "Negative Earnings Per Share",
     "text": "Gilead Sciences is currently reporting a negative EPS of -$2.65, which raises concerns about the company's profitability and the sustainability of its dividend.",
     "source": "Financial Statements"
    },
    {
     "type": "Neutral",
     "title": "Flat Current Quarter Revenue Growth",
     "text": "Projected revenue growth for the current quarter is 0.00% year-over-year, indicating a lack of immediate top-line expansion, though modest growth is anticipated in subsequent periods.",
     "source": "Wall Street Estimates"
    },
    {
     "type": "Bullish",
     "title": "Positive Analyst Price Targets",
     "text": "The median analyst price target for GILD is $160.00, suggesting a potential 10.5% upside from the current price, supported by a 'Buy' consensus from 28 analysts.",
     "source": "Analyst Ratings"
    },
    {
     "type": "Bullish",
     "title": "Above Key Moving Averages",
     "text": "GILD is trading above its 50-day and 200-day moving averages ($137.74 and $134.65), indicating a generally positive long-term trend and potential support levels.",
     "source": "Technical Analysis"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Gilead Sciences (GILD) presents a mixed fundamental picture, with its Price-to-Earnings (P/E) ratio not applicable due to negative Earnings Per Share (EPS) of -$2.65. This indicates the company is currently loss-making on a per-share basis, a significant concern for valuation. The company's Return on Equity (ROE) is also low at 6.9%, below the sector median of 6.9%, suggesting inefficient use of shareholder equity. Revenue growth is projected to be flat at 0.00% for the current quarter, though it is expected to pick up to 3.00% next quarter and 4.00% for the full year. This modest growth is slightly above the sector median revenue growth of 8.1%. The company's dividend yield stands at approximately 2.24%, providing some return to shareholders, but the negative EPS raises questions about the sustainability of this payout without further debt or equity financing.",
    "Gilead Sciences (GILD) has shown mixed earnings performance recently. The most recent quarter (August 4, 2026) reported an EPS of -$6.75, which was a 6.9% beat against an estimate of -$7.25, though the stock price declined by 2.58%. Prior to that, the May 7, 2026, quarter also saw a beat (2.03 actual vs. 1.91 estimate) but resulted in a price drop of 2.04%. The company did experience a positive price reaction in the February 10, 2026, quarter with a beat and a 5.82% stock increase, and a significant beat in the October 30, 2025, quarter with a 1.14% price gain.",
    "The primary risk for Gilead Sciences (GILD) is the significant insider selling, with nearly $100 million in dispositions and no reported purchases, suggesting a lack of confidence from management. Additionally, the company is currently loss-making with negative EPS of -$2.65, which poses a fundamental risk to its valuation and long-term financial health. Flat revenue growth in the current quarter also presents a near-term challenge, despite modest growth expectations for the remainder of the year."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "179.56B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-2.65"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "2.24%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "157.29"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "108.46"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Neutral SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($137.74) above the 200-day SMA ($134.65), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Neutral",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "53.04"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "3.06"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "137.74"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "134.65"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.22",
    "Correlation with Nasdaq 100 (QQQ)": "+0.12",
    "Correlation with Bitcoin (BTC)": "-0.09",
    "Correlation with Gold (XAU)": "+0.05"
   }
  },
  {
   "id": "trade-plans",
   "title": "GILD Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (53.0) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$147.66",
    "TARGET 2": "$150.53",
    "TARGET 3": "$154.83",
    "STOP LOSS": "$139.06"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+3.66%",
    "Average Feb return": "-2.05%",
    "Average Mar return": "-1.12%",
    "Average Apr return": "-1.23%",
    "Average May return": "-0.92%",
    "Average Jun return": "+3.01%",
    "Average Jul return": "+1.33%",
    "Average Aug return": "+2.22%",
    "Average Sep return": "-0.69%",
    "Average Oct return": "+0.43%",
    "Average Nov return": "+2.72%",
    "Average Dec return": "-2.04%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.65%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in GILD in September 2016 would be worth about $18,365 today, compared with about $35,030 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in GILD today could grow to about $19,130 by 2036 in the base case, with a bull case near $53,925 and a bear case around $6,787. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "GILD Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $188 for GILD by 2030 in the base case, from $145 today (1.3x over 4 years). The downside path ends near $97.46. These are outcomes of a Monte Carlo simulation run on GILD's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using GILD's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "GILD simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$111",
        "$155",
        "$214"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$104",
        "$165",
        "$262"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$99.72",
        "$176",
        "$310"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$97.46",
        "$188",
        "$362"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$96.25",
        "$200",
        "$417"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$95.77",
        "$214",
        "$477"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$95.82",
        "$228",
        "$543"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$96.30",
        "$243",
        "$615"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$97.14",
        "$260",
        "$694"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$98.28",
        "$277",
        "$781"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "ILMN Illumina Inc. NASDAQ $206.28 +2.49%",
     "url": "https://clearank.com/stock/ilmn-stock-analysis/"
    },
    {
     "text": "NTRA Natera, Inc. NASDAQ $326.14 -1.26%",
     "url": "https://clearank.com/stock/natera-ntra/"
    },
    {
     "text": "HCA HCA Healthcare, Inc. NYSE $417.37 -1.06%",
     "url": "https://clearank.com/stock/hca-healthcare-hca/"
    },
    {
     "text": "MDT Medtronic NYSE $90.78 -0.9223%",
     "url": "https://clearank.com/stock/medtronic-mdt/"
    },
    {
     "text": "AGL agilon health, Inc. NYSE $92.60 -1.06%",
     "url": "https://clearank.com/stock/agl-stock-analysis/"
    },
    {
     "text": "ZTS Zoetis Inc. NYSE $72.96 +0.1372%",
     "url": "https://clearank.com/stock/zts-stock-analysis/"
    },
    {
     "text": "MRK Merck & Co., Inc. NYSE $147.53 -0.6264%",
     "url": "https://clearank.com/stock/merck-mrk/"
    },
    {
     "text": "FBRX Forte Biosciences, Inc. NASDAQ $76.99 +0.00%",
     "url": "https://clearank.com/stock/fbrx-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Compare GILD",
   "links": [
    {
     "text": "GILD vs BMY Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/gild-vs-bmy/"
    },
    {
     "text": "EOG vs DVN Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/eog-vs-dvn/"
    },
    {
     "text": "VGT vs QQQ Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vgt-vs-qqq/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "GILD Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$99.9M",
    "Insiders": "15",
    "Avg Transaction": "$1.7M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in GILD",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Nov 29, 2024",
       "cells": [
        "DICKINSON ANDREW D Chief Financial Officer",
        "Sell",
        "248.6K",
        "$23.1M"
       ]
      },
      {
       "label": "Feb 5, 2026",
       "cells": [
        "O'DAY DANIEL PATRICK Chief Executive Officer",
        "Sell",
        "115.6K",
        "$17.3M"
       ]
      },
      {
       "label": "Jan 23, 2026",
       "cells": [
        "O'DAY DANIEL PATRICK Chief Executive Officer",
        "Sell",
        "115.6K",
        "$15.6M"
       ]
      },
      {
       "label": "Nov 27, 2024",
       "cells": [
        "PARSEY MERDAD V Officer",
        "Sell",
        "164.2K",
        "$15.1M"
       ]
      },
      {
       "label": "Feb 12, 2025",
       "cells": [
        "DICKINSON ANDREW D Chief Financial Officer",
        "Sell",
        "137.7K",
        "$14.1M"
       ]
      },
      {
       "label": "Jan 31, 2025",
       "cells": [
        "DICKINSON ANDREW D Chief Financial Officer",
        "Sell",
        "142.2K",
        "$13.8M"
       ]
      },
      {
       "label": "Nov 12, 2025",
       "cells": [
        "TELMAN DEBORAH H General Counsel",
        "Sell",
        "53.6K",
        "$6.6M"
       ]
      },
      {
       "label": "Feb 17, 2026",
       "cells": [
        "MERCIER JOHANNA Officer",
        "Sell",
        "28.0K",
        "$4.3M"
       ]
      },
      {
       "label": "Aug 17, 2026",
       "cells": [
        "MERCIER JOHANNA Officer",
        "Sell",
        "28.0K",
        "$3.9M"
       ]
      },
      {
       "label": "May 15, 2026",
       "cells": [
        "MERCIER JOHANNA Officer",
        "Sell",
        "28.0K",
        "$3.7M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Gilead+Sciences%2C+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Gilead Sciences' (GILD) current stock price and fair value?",
   "answer": "Gilead Sciences (GILD) is currently trading at $144.81. Based on the provided fair value metric, the stock is not indicating any immediate upside, as the fair value is also estimated at $144.81."
  },
  {
   "question": "Is Gilead Sciences (GILD) stock a buy right now?",
   "answer": "Gilead Sciences (GILD) has a 'Hold' consensus rating from our AI analysis, with a consensus score of 55. Wall Street analysts have a more positive 'Buy' consensus with a score of 72, and a median price target of $160.00, suggesting a 10.5% upside. However, significant insider selling and negative EPS warrant caution."
  },
  {
   "question": "What are the biggest risks facing Gilead Sciences (GILD)?",
   "answer": "The most significant risks for Gilead Sciences (GILD) include substantial insider selling totaling $99.9 million, negative EPS of -$2.65 indicating current unprofitability, and flat revenue growth in the most recent quarter. These factors collectively present considerable headwinds."
  },
  {
   "question": "How is Gilead Sciences (GILD) performing in terms of revenue growth compared to its peers?",
   "answer": "Gilead Sciences (GILD) is projected to have flat revenue growth (0.00%) for the current quarter, which is below the sector median of 8.1%. While growth is expected to improve in subsequent quarters and for the full year, the current stagnation is a concern."
  },
  {
   "question": "What is the analyst price target for Gilead Sciences (GILD)?",
   "answer": "The median analyst price target for Gilead Sciences (GILD) is $160.00, with a high of $180.00 and a low of $123.00. This implies an upside potential of 10.5% from the current stock price of $144.81."
  },
  {
   "question": "What is Gilead Sciences' (GILD) dividend yield and is it sustainable?",
   "answer": "Gilead Sciences (GILD) offers a dividend yield of approximately 2.24%. Given the company's current negative EPS of -$2.65, the sustainability of this dividend without impacting future growth or requiring additional financing should be carefully monitored."
  },
  {
   "question": "What does the insider trading activity suggest about Gilead Sciences (GILD)?",
   "answer": "Insider trading activity for Gilead Sciences (GILD) indicates heavy selling pressure, with $99.9 million in total sales and no reported purchases. This heavy insider selling verdict suggests a lack of confidence from insiders and is a notable bearish indicator."
  },
  {
   "question": "What is Gilead Sciences' (GILD) stock forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Gilead Sciences' (GILD) stock forecast for 2030 shows a base case price of $187.71, a downside projection of $97.46, and an upside potential of $361.52. These figures represent statistical outcomes, not guaranteed price targets."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "ILMN",
    "name": "Illumina Inc. NASDAQ",
    "price": "$206.28",
    "change": "+2.49%",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "NTRA",
    "name": "Natera, Inc. NASDAQ",
    "price": "$326.14",
    "change": "-1.26%",
    "url": "https://clearank.com/stock/natera-ntra/"
   },
   {
    "ticker": "HCA",
    "name": "HCA Healthcare, Inc. NYSE",
    "price": "$417.37",
    "change": "-1.06%",
    "url": "https://clearank.com/stock/hca-healthcare-hca/"
   },
   {
    "ticker": "MDT",
    "name": "Medtronic NYSE",
    "price": "$90.78",
    "change": "-0.9223%",
    "url": "https://clearank.com/stock/medtronic-mdt/"
   },
   {
    "ticker": "AGL",
    "name": "agilon health, Inc. NYSE",
    "price": "$92.60",
    "change": "-1.06%",
    "url": "https://clearank.com/stock/agl-stock-analysis/"
   },
   {
    "ticker": "ZTS",
    "name": "Zoetis Inc. NYSE",
    "price": "$72.96",
    "change": "+0.1372%",
    "url": "https://clearank.com/stock/zts-stock-analysis/"
   },
   {
    "ticker": "MRK",
    "name": "Merck & Co., Inc. NYSE",
    "price": "$147.53",
    "change": "-0.6264%",
    "url": "https://clearank.com/stock/merck-mrk/"
   },
   {
    "ticker": "FBRX",
    "name": "Forte Biosciences, Inc. NASDAQ",
    "price": "$76.99",
    "change": "+0.00%",
    "url": "https://clearank.com/stock/fbrx-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "GILD vs BMY Comparison",
    "name": "",
    "url": "https://clearank.com/compare/gild-vs-bmy/"
   },
   {
    "ticker": "EOG vs DVN Comparison",
    "name": "",
    "url": "https://clearank.com/compare/eog-vs-dvn/"
   },
   {
    "ticker": "VGT vs QQQ Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vgt-vs-qqq/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "JCI",
    "text": "Johnson Controls International",
    "url": "https://clearank.com/stock/jci-stock-analysis/"
   },
   {
    "ticker": "BLDR",
    "text": "Builders FirstSource Inc.",
    "url": "https://clearank.com/stock/bldr-stock-analysis/"
   },
   {
    "ticker": "EIS",
    "text": "iShares MSCI Israel ETF",
    "url": "https://clearank.com/etf/eis-etf-analysis/"
   },
   {
    "ticker": "GWRE",
    "text": "Guidewire Software Inc.",
    "url": "https://clearank.com/stock/gwre-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "DELL",
    "text": "↑ 10.23%",
    "url": "https://clearank.com/stock/dell-technologies-dell/"
   },
   {
    "ticker": "IMSR",
    "text": "↓ 9.79%",
    "url": "https://clearank.com/stock/terrestrial-energy-imsr/"
   },
   {
    "ticker": "SWKS",
    "text": "↑ 9.79%",
    "url": "https://clearank.com/stock/skyworks-solutions-swks/"
   },
   {
    "ticker": "EIGEN/USD",
    "text": "↑ 9.39%",
    "url": "https://clearank.com/crypto/eigen-usd-crypto-analysis/"
   },
   {
    "ticker": "EGLD/USD",
    "text": "↓ 9.23%",
    "url": "https://clearank.com/crypto/egld-usd-crypto-analysis/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "BIIB",
    "text": "Biogen Inc.",
    "url": "https://clearank.com/stock/biib-stock-analysis/"
   },
   {
    "ticker": "BMY",
    "text": "Bristol-Myers Squibb",
    "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/"
   },
   {
    "ticker": "JNJ",
    "text": "Johnson & Johnson",
    "url": "https://clearank.com/stock/johnson-johnson-jnj/"
   },
   {
    "ticker": "LLY",
    "text": "Eli Lilly",
    "url": "https://clearank.com/stock/eli-lilly-lly/"
   },
   {
    "ticker": "MRK",
    "text": "Merck",
    "url": "https://clearank.com/stock/merck-mrk/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "url": "https://clearank.com",
     "sameAs": [
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "email": "info@clearank.com",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise",
     "numberOfEmployees": {
      "@type": "QuantitativeValue",
      "value": "40"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/06/GILD-gilead-sciences-analysis-2026-06.png",
     "url": "https://clearank.com/wp-content/uploads/2026/06/GILD-gilead-sciences-analysis-2026-06.png",
     "width": "1280",
     "height": "720",
     "caption": "Gilead Sciences (GILD) stock price analysis chart for June 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/gilead-sciences-gild/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/gilead-sciences-gild/",
        "name": "Gilead Sciences (GILD) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/gilead-sciences-gild/#webpage",
     "url": "https://clearank.com/stock/gilead-sciences-gild/",
     "name": "Gilead Sciences (GILD) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-06-17T09:07:47+00:00",
     "dateModified": "2026-09-11T11:47:26+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/GILD-gilead-sciences-analysis-2026-06.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/gilead-sciences-gild/#breadcrumb"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/writer/clearank/",
     "name": "CleaRank",
     "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.",
     "url": "https://clearank.com/writer/clearank/",
     "image": {
      "@type": "ImageObject",
      "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "caption": "CleaRank",
      "inLanguage": "en-US"
     },
     "sameAs": [
      "https://clearank.com/",
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     },
     "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg"
    },
    {
     "@type": "Article",
     "headline": "Gilead Sciences (GILD) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-06-17T09:07:47+00:00",
     "dateModified": "2026-09-11T11:47:26+00:00",
     "author": {
      "@id": "https://clearank.com/writer/clearank/",
      "name": "CleaRank"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "description": "Gilead Sciences, Inc. (GILD) stock: Healthcare, Drug Manufacturers - General. $179.6B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "name": "Gilead Sciences (GILD) Stock Forecast & Price Target (2026)",
     "@id": "https://clearank.com/stock/gilead-sciences-gild/#richSnippet",
     "isPartOf": {
      "@id": "https://clearank.com/stock/gilead-sciences-gild/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/GILD-gilead-sciences-analysis-2026-06.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/gilead-sciences-gild/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FinancialProduct",
   "name": "Gilead Sciences, Inc. (GILD)",
   "tickerSymbol": "GILD",
   "url": "https://clearank.com/stock/gilead-sciences-gild/",
   "description": "AI-powered financial analysis for Gilead Sciences, Inc. (GILD) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.",
   "exchange": "NASDAQ",
   "offers": {
    "@type": "Offer",
    "price": 144.81,
    "priceCurrency": "USD",
    "availability": "https://schema.org/InStock",
    "url": "https://clearank.com/stock/gilead-sciences-gild/",
    "priceValidUntil": "2026-09-12"
   }
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Gilead Sciences' (GILD) current stock price and fair value?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Gilead Sciences (GILD) is currently trading at $144.81. Based on the provided fair value metric, the stock is not indicating any immediate upside, as the fair value is also estimated at $144.81."
     }
    },
    {
     "@type": "Question",
     "name": "Is Gilead Sciences (GILD) stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Gilead Sciences (GILD) has a 'Hold' consensus rating from our AI analysis, with a consensus score of 55. Wall Street analysts have a more positive 'Buy' consensus with a score of 72, and a median price target of $160.00, suggesting a 10.5% upside. However, significant insider selling and negative EPS warrant caution."
     }
    },
    {
     "@type": "Question",
     "name": "What are the biggest risks facing Gilead Sciences (GILD)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The most significant risks for Gilead Sciences (GILD) include substantial insider selling totaling $99.9 million, negative EPS of -$2.65 indicating current unprofitability, and flat revenue growth in the most recent quarter. These factors collectively present considerable headwinds."
     }
    },
    {
     "@type": "Question",
     "name": "How is Gilead Sciences (GILD) performing in terms of revenue growth compared to its peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Gilead Sciences (GILD) is projected to have flat revenue growth (0.00%) for the current quarter, which is below the sector median of 8.1%. While growth is expected to improve in subsequent quarters and for the full year, the current stagnation is a concern."
     }
    },
    {
     "@type": "Question",
     "name": "What is the analyst price target for Gilead Sciences (GILD)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The median analyst price target for Gilead Sciences (GILD) is $160.00, with a high of $180.00 and a low of $123.00. This implies an upside potential of 10.5% from the current stock price of $144.81."
     }
    },
    {
     "@type": "Question",
     "name": "What is Gilead Sciences' (GILD) dividend yield and is it sustainable?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Gilead Sciences (GILD) offers a dividend yield of approximately 2.24%. Given the company's current negative EPS of -$2.65, the sustainability of this dividend without impacting future growth or requiring additional financing should be carefully monitored."
     }
    },
    {
     "@type": "Question",
     "name": "What does the insider trading activity suggest about Gilead Sciences (GILD)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insider trading activity for Gilead Sciences (GILD) indicates heavy selling pressure, with $99.9 million in total sales and no reported purchases. This heavy insider selling verdict suggests a lack of confidence from insiders and is a notable bearish indicator."
     }
    },
    {
     "@type": "Question",
     "name": "What is Gilead Sciences' (GILD) stock forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Gilead Sciences' (GILD) stock forecast for 2030 shows a base case price of $187.71, a downside projection of $97.46, and an upside potential of $361.52. These figures represent statistical outcomes, not guaranteed price targets."
     }
    }
   ]
  }
 ]
}